latrepirdine (Dimebon, dimeboline, dimebolin)
Jump to navigation
Jump to search
Indications
- possibily of benefit in Alzheimer's disease
- investigational agent for treatment of Huntington's disease
- used in Russia for decades to treat Alzheimer's disease
- not effective for Alzheimer's disease
Dosage
Adverse effects
- generally safe & well tolerated
- dry mouth
- depression
Mechanism of action
- antihistamine
- weak cholinesterase inhibitor
- may be neuroprotective
Clinical trials
- CONNECTION trial
More general terms
References
- ↑ Doody RS et al, Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to- moderate Alzheimer's disease: A randomised, double-blind, placebo-controlled study. Lancet 2008, 372:207 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18640457
- ↑ LA Times, March 4, 2010 http://latimesblogs.latimes.com/booster_shots/2010/03/dimebon-alzheimers-disease-drug.html
- ↑ Pfizer Press Release Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program http://www.pfizer.com/news/press_releases/pfizer_press_releases.jsp?rssUrl=http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp
- ↑ Dimebon Clinical Trials http://www.dimebontrials.com